Sarcolectin (SCL) is a nonspecific stimulator of cellular DNA synthesis that was found in all animal sera tested to date. It inhibits the established interferon (IFN)-dependent antiviral state, restoring cells to their normal status. In this study, we examined the excretion/secretion of the IFN antagonist SCL in sera from healthy donors and in sera collected during different periods of human immunodeficiency virus type 1 (HIV-1) infection. We followed HIV-1-infected patients during all stages of development (seroconversion, initial and advanced phases of AIDS) and found a significant increase in SCL in sera of HIV-infected patients compared with seronegative subjects used as controls. This increase was established during seroconversion, and then the titers leveled off. In the final stage of the disease, the SCL titer increased again very significantly. We attribute this rapid rise to the virus-dependent destruction of T cells that can no longer be repaired. The high SCL level observed at this final stage, which is most predictive of the disease's progression, suggests that the action, rather than the production, of IFN is impaired. 305 
INTRODUCTION H
UMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) infection elicits a broad range of host responses and is associated with dysregulation of cytokine production. (1) Thus, a number of cytokines-interleukin-1 (IL-1), IL-6, tumor necrosis factora (TNF-a), interferon-a (IFN-a), and IFN-g-are produced at an increased level in vivo. (2) IFNs are pleiotropic cytokines that exhibit multiple biologic effects on cells and tissues, and they have long been recognized as antiviral agents. Further investigations into the role of these cytokines are underway. Their action involves binding to the IFN cell membrane receptor and initiation of an intracellular signal transduction cascade. As an antagonist of IFNs, sarcolectin (SCL) blocks the synthesis of secondary proteins promoted by IFN, which restores to the cells the capacity to stimulate DNA synthesis. Thus, virus sensitivity in the cells reappears. (3) We show here that SCL may play a role in HIV-1 pathogenesis by taking into account the repeated immune challenges to which HIV-1-infected patients are repeatedly exposed. We hypothesize that an SCL-IL-2-IFN cycle operates during normal T cell clonal expansion. The study of this cycle could help to improve our understanding of the HIV-1-induced pathologic processes. This, in turn, would put us on the path to therapy for restoring the balance between these three different proteins. A preliminary report on this subject was published earlier. (4) 
MATERIALS AND METHODS

Polyclonal monospecific, monoclonal, and oligopeptide antibodies
The specific antibodies raised against the N-acetyl neuraminic acid (NANA) chromatography-purified 55-kDa SCL, as described in previous studies, were used. (5) We also employed antibodies to oligopeptides SCL 41-55, 81-95, and 455-469 synthesized by Neosystem (Strasbourg, France). In some experiments, commercial K2C7 monoclonal antibodies (mAb) were used (Sigma C-6417) because of the close structural relationship between SCL and mesothelial cytokeratin K2C7 as control. (6) ELISA assay ELISA assay was performed by the routine procedure. The antigen was found to 96-well EIA/RIA flat-bottom plates (Costar, Cambridge, MA) by incubating the preparation overnight at 4°C or 2 h at ambient temperature. Unbound material was discarded, and the plates were washed three times with 0.05 M carbonate-bicarbonate buffer, pH 9.6. To eliminate unspecific binding, wells were blocked with 5% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) added at 37°C for 2 h. After washing three times with PBS containing 0.05% Tween 20, primary antibodies at 1:100 were added and incubated 1 h at 37°C. Bound antibody was probed with a secondary antibody (Amersham antirabbit Ig F(ab9) at a 1:2000 dilution) (Amersham, Arlington Heights, IL) for 1 h after three washings. For controls, three preparations were employed, a negative control at the highest concentration of the antigen for which the specific 55-kDa was omitted or replaced by normal rabbit serum and two positive controls: (1) serial dilutions of BSA used as reference antigen to exclude nonspecific binding due to SCL and (2) a known positive reference SCL control antigen from a pool of normal sera. The plates were washed three times, and enzymatic reactions were carried out at ambient temperature by adding H 2 O 2 and o-phenylenediamine (Abbott S.A., France). Reactions were stopped after 4 min by addition of 100 ml of 2 N H 2 SO 4 . Color development was measured bichromatically at 490 and 630 nm.
Immunoblotting analysis
Specimens for the detection of SCL were submitted to 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using standard methods. Proteins were transferred onto nitrocellulose membranes via electroblotting. Membranes were blocked 2 h with PBS containing 0.05% Tween 20 and 5% skim milk at ambient temperature and then incubated with primary antibodies overnight at 4°C (or 2 h at ambient temperature). The following antibodies were used: antibodies raised against NANApurified SCL antigens, oligopeptide antibodies synthesized according to the SCL sequences listed above, or commercial mAb K2C7 (Sigma C-6417) as reported (6) 
RESULTS
Study subjects
Patients from the Hôpital Saint Antoine in Paris, who form the majority of the study population, were divided in these early studies into four categories according to the state of development of the HIV infection: (A) 60 HIV-1-negative control patients from the same hospital and in comparable age groups, (B) 13 seroconverted patients (CDC stage I-II), (C) 15 with symptoms usually observed during this phase (CDC stage III), and (D) 16 more advanced cases (CDC stage IV). (7) For all study groups, we calculated the mean value and the standard deviation (SD) for each SCL titration by dose-response assay. Interpretation of the results was supported by statistical analysis using the r correlation coefficient. (8) The majority of the sera were obtained from the service of Medecine Interne, Hôpital Saint Antoine in Paris. Some others, from patients in the advanced stages of AIDS, were provided by the service of Professor Lurmuha at the Clinique Universitaire, Kinshasa (R.D.C.).
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FIG. 1. Serum SCL titers in control subjects and AIDS patients. SCL titers in sera during different phases of the disease. The different stages follow the progression of the disease and are classified as follows: 60 controls; 13 seroconverted patients stage (CDC I-II); 15 CDC stage III patients with generalized lymphadenopathy with or without common symptoms; 16 CDC stage IV patients with opportunistic infections or secondary tumors. (5) The assay was performed using antisera developed against a NANA affinity chromatography highly purified SCL antigen. The SCL concentration increases during seroconversion and progresses with the disease.
Statistical analysis
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ELISA assay using monospecific antibody developed against the highly purified SCL 55-kDa antigen in rabbits
The results (Fig. 1) show that (1) between primary infection and CDC stage I-II, a highly significant increase in SCL antigen can be detected in all sera of HIV-1-infected patients compared with the control HIV-1-seronegative individuals, (2) throughout CDC I-II and the first phase of CDC III, the SCL titers are stable, (3) during the latter phase of CDC III they decrease slightly, and (4) during CDC IV, the SCL titers increase significantly, progressing with the severity of the disease.
We completed these first experiments with sera raised against the full-length SCL-NANA affinity chromatography-purified antigen, with other tests aimed at increasing immune specificity and defining the different immune reactions. For this purpose, we raised oligopeptide antibodies to selected domains of the cloned gene, as described in Materials and Methods.
Selection, identification, and SCL specificity of polyclonal oligopeptide antibodies directed against three domains of the cloned protein
The structure of the cloned SCL cDNA was reported in a previous publication. (6) Briefly, the protein consists of four ahelices with a b sheet on each extremity. On the amino-end, the b sheet carries most of the lectinic properties, mainly in amino acids 41-55. On the carboxyl-end, the b sheet is very short and has a highly antigenic segment in 455-469. In between, oligopeptides 81-95 are located on the first a-helix. All sera were assayed separately with each of the antibodies raised to the three oligopeptides provided by the cloned gene. As reference, commercial mAb to the monomer of K7 cytokeratin was employed (Table 1) .
Evaluation of oligopeptide SCL polyclonal antibodies using seven randomly selected HIV-1-positive patient sera
To evaluate the affinity of the antibodies raised to the different oligopeptide antigens, we studied in an ELISA assay seven randomly selected HIV-1-positive sera. Each was assayed with the three different SCL oligopeptide antibodies. The results are shown in Figure 2 . All the antibodies not only recognized their specific oligopeptide domain of the cloned molecule but also reacted with the whole SCL protein, but, as expected, with variable affinity. In all cases, the antibody raised against the terminal oligopeptide 455-469 responded significantly better in the ELISA assay than did the 41-55 antibody. The antibodies directed against amino acids 81-95 to the first helical antigen performed poorly. We, therefore, selected for further studies the highly specific 455-469 terminal amino acid. As shown in another report, (9) these antibodies are also identified with known SCL-positive commercial mAb and SCL-positive serum from an identified osteosarcoma patient.
Study of sera from control donors and patients in CDC groups I-II, III, or IV using the antibody raised to oligopeptide 455-469 aa
In four further experiments on sera of individual patients, 21 HIV-1-seronegative controls and 21 HIV-1-seropositive individuals were studied using the antibody raised to oligopeptide 455-469. The four experiments were performed in parallel under the same conditions and using the same antibody preparation ( Table 2 ). The patients were classified into groups CDC I-II, CDC III, and CDC IV.
In the four experiments, compared with controls, phase CDC I-II sera show a highly significant increase in SCL production. The levels stabilize after seroconversion. The results of exper- a Four independent experiments are presented. ELISA titers are expressed using dose-response assays. The linearity for each experimental value is controlled. The titer is the dilution that contains at least 100 OD units of SCL. BSA is used as negative control, and the positive control is highly purified SCL oligopeptides. At the 1; 6400 dilution, the antibody 455-469 recognizes 0.37 ng SCL antigen. Each experimental set was performed at the same time with the same reagents.
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FIG. 3.
SCL proteins in sera of controls and CDC III-IV patients studied by Western blot, using commercial mAb. (7) From left to right: Lane 1, 1:100 HIV-1-negative serum; lane 2, PBMC media from conditioned culture; the third passage contains 2% serum. We use the first serum-free passage in the presence of IL-2 (100 UI/ml). The 55-kDa SCL band is seen as well as the 65-kDa band, considered to be a result of binding of SCL fragments or molecules on residual albumin. (7) No other band can be seen in the corresponding SDS gel. Thus, the only visible protein detected in the serum-free medium is SCL (data to be published in more detail); lanes 3-5, biopsy specimen from osteosarcoma patients, maintained in serum-free medium; lane 4, control medium; lane 6, molecular weight markers; lanes 7-12, 1:100 sera from advanced cases of AIDS. In all specimens, the 55-kDa band is very intense when compared to the HIV-1-negative serum. The 65-kDa band is practically absent in lane 10, and the 55-kDa band is predominant. This case was considered to be very severe. In all AIDS cases, the 30-kDa band seen only in the lanes provided by the severe cases, suggests cross-reactivity with a dimer of galactose-binding lectin (galectin). iments 1 and 2 indicate that during the transition from CDC I-II to CDC III, the serum SCL titers remain high but decrease slightly over time. The results from experiments 3 and 4 show that between CDC I-II and CDC IV phases, the serum SCL titers increases very significantly. The results from phase CDC III in experiments 1 and 2 compared with phase CDC IV in experiments 3 and 4 show the same increased serum SCL titers. This burst of SCL release is established during the final phase of the disease, when the plasma viral load is high and the CD4 1 T cell count is collapsed.
Western blotting analysis
The highly specific quantitative data obtained enabled us to incriminate SCL in the HIV-1-dependent infectious process. It was, therefore, important to identify SCL in sera using Western blots to estimate the size and the specificity of the SCL molecule.
The results of Western blots of 6 patients with advanced AIDS are shown in Figure 3 . Five of them were sera from Kinshasa, and one was from Paris. For controls we used (1) one seronegative serum from an adult, (2) 4-fold concentrated conditioned medium from a healthy adult (peripheral blood mononuclear cells [PBMC] grown in the absence of serum), (3) two HIV-1-seronegative biopsy specimens from a Children's Hospital in Paris, (4) control medium, (5) serum from a patient ill with osteogenic sarcoma (from the same hospital), (6) protein size markers, and (7-12) sera from 6 advanced AIDS cases.
All sera were assayed with commercial K7 mAb. In all severe cases of AIDS, the 55-kDa bands are far more intensively labeled than in HIV-1-negative sera or other controls. The 65-kDa label is complex, resulting from the binding of some 55-kDa scattered SCL protein molecule remains to albumin. The dimer 97-110 kDa proteins were poorly recognized, as was the 67-kDa protein. This suggests a possible regulatory interaction between SCL and albumin that could behave as a transport molecule. (5) It is of interest that these antibodies react intensively with the 55-kDa bands from AIDS. The 30-kDa bands correspond to a 14-kDa galactose-binding lectin (galectin) dimer.
DISCUSSION
It is important to stress that two independent sets of experiments, one using monospecific antibodies raised to the 55-kDa SCL protein and the other using the 455-469 oligopeptide antibody raised to the cloned protein, gave comparable results and generated similar conclusions. They show that during HIV-1 seroconversion a significant increase in SCL excretion/secretion in the patients' sera can be observed, followed by a leveling off. This is clearly established by the highly sensitive ELISA assays with three different SCL antibodies: (1) monospecific, raised against the NANA chromatography-purified 55-kDa SCL, (2) directed against the terminal oligopeptide of the cloned protein, and (3) commercial mouse mAb. The oligopeptide antibodies are of special interest for studying both the sensitivity and the specificity of the SCL immune assays.
During the CDC IV phase, the serum SCL titers increase in parallel with the loss of IFN sensitivity of the cells, as SCL inhibits the functions of the IFN-dependent secondary proteins, as previously suggested. (10) SCL can promote a loss of physiologic refractoriness to repeated IFN inductions. (11) This might explain, at least in part, the ineffectiveness of even the high IFN titers during this final period of AIDS. In parallel, the HIV virus load augments, and the CD4 1 T cell count collapses. As reported by Hendel et al., (10) sera from "fast progressor" patients (CDC III-IV) contain more IFN than sera from long-term "no progressors" (CDC I-II). The excess amount of these ineffective IFNs, which can accumulate in the serum, could damage some cells.
It is of interest to connect these data to other pathologic disorders. An excess of such circulating ineffective IFNs has already been reported in systemic lupus erythematosus (12) and various autoimmune diseases, in which large amounts of circulating IFNs are regularly detected. These IFNs seemingly aggravate the pathologic process, and this might be connected to comparable excesses of SCL. (13) Our data suggest that the imbalance created in the normal SCL-IL-2-IFN cycle (9, 14, 15) HIV-1 infection is very difficult to overcome.
